Trial · NCT04370834
Tocilizumab for Patients With Cancer and COVID-19 Disease
NCT04370834, Phase 2, Terminated, National Cancer Institute (NCI); results first posted 2021-06-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tocilizumab for Patients With Cancer and COVID-19 Disease. Trials, record NCT04370834. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04370834
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tocilizumab for Patients With Cancer and COVID-19 Disease
- NCT number
- NCT04370834
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis, Severe Acute Respiratory Distress Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Interventions
- Tocilizumab
- First posted
- 2020-05-01
- Last updated
- 2025-02-04
- Results first posted
- 2021-06-04
- Limitations and caveats
- Early termination as randomized data did not support continuation.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With at Least 1 Point Reduction in Score on 7-category Clinical Status Ordinal Scale | Day 14 after tocilizumab administration | 7-category Clinical Status Ordinal Scale: 1. Discharge 2. Non-ICU, hospital ward, No O2 3. Non-ICU, hospital ward, on O2 4. ICU or non-ICU, requires non-invasive ventilatory support or high flow O2 5. ICU requires mechanical or imminent ventilation/intubation 6. ICU requires ECMO and additional O2 support and organ support, e.g. vasopressors, renal replacement therapy 7. Death |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With at Least 1 Point Reduction in Score on 7-category Clinical Status Ordinal Scale | Day 14 after tocilizumab administration | No patients were accrued to Cohorts A2, B1, or B2. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With at Least 1 Point Reduction in Score on 7-category Clinical Status Ordinal Scale | Cohort A1 | 1 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Other (Tocilizumab) | 1 | |
| Overall Study | COMPLETED | Other (Tocilizumab) | 1 | |
| Overall Study | NOT COMPLETED | Other (Tocilizumab) | 0 |
Source ClinicalTrials.gov
Adverse events24
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Alanine aminotransferase increased | Investigations | Cohort A1 | 1 | 1 | 1 |
| other | Alanine aminotransferase increased | Investigations | Cohort A2 | 0 | 0 | 0 |
| other | Alanine aminotransferase increased | Investigations | Cohort B1 | 0 | 0 | 0 |
| other | Alanine aminotransferase increased | Investigations | Cohort B2 | 0 | 0 | 0 |
| other | Aspartate aminotransferase increased | Investigations | Cohort A1 | 1 | 1 | 1 |
| other | Aspartate aminotransferase increased | Investigations | Cohort A2 | 0 | 0 | 0 |
| other | Aspartate aminotransferase increased | Investigations | Cohort B1 | 0 | 0 | 0 |
| other | Aspartate aminotransferase increased | Investigations | Cohort B2 | 0 | 0 | 0 |
| other | Blood bilirubin increased | Investigations | Cohort A1 | 1 | 1 | 1 |
| other | Blood bilirubin increased | Investigations | Cohort A2 | 0 | 0 | 0 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cohort A1 | 1 | 1 |
| Total, all-cause mortality | Cohort A2 | 0 | 0 |
| Total, all-cause mortality | Cohort B1 | 0 | 0 |
| Total, all-cause mortality | Cohort B2 | 0 | 0 |
| Total, other adverse events | Cohort A1 | 1 | 1 |
| Total, other adverse events | Cohort A2 | 0 | 0 |
| Total, other adverse events | Cohort B1 | 0 | 0 |
| Total, other adverse events | Cohort B2 | 0 | 0 |
| Total, serious adverse events | Cohort A1 | 1 | 1 |
| Total, serious adverse events | Cohort A2 | 0 | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04370834
GET https://conductscience.org/api/trials/v1/NCT04370834/events?page=2